TY - JOUR
T1 - Retrospective analysis of elderly patients > or = 60 years of age with acute leukemia
AU - Tabata, M.
AU - Yoshida, M.
AU - Izumi, T.
AU - Kawano, C.
AU - Kuribara, R.
AU - Toshima, M.
AU - Omine, K.
AU - Takatoku, M.
AU - Uchida, M.
AU - Kirito, K.
AU - Miyazato, A.
AU - Takahashi, H.
AU - Hoshino, M.
AU - Terui, Y.
AU - Tomizuka, H.
AU - Otsuki, T.
AU - Shimizu, R.
AU - Tsunoda, J.
AU - Muroi, K.
AU - Furukawa, Y.
AU - Amemiya, Y.
AU - Imagawa, S.
AU - Komatsu, N.
AU - Suzuki, T.
AU - Miura, Y.
PY - 1998/3
Y1 - 1998/3
N2 - A retrospective analysis was performed on 76 consecutive elderly patients with acute leukemia aged 60 years or more (48 men, 28 women). Forty patients were 60-69 years old, 28 were 70-79 years old and 8 were > or = 80 years old. There were 55 patients with acute myelogenous leukemia (AML), 13 acute lymphoblastic leukemia (ALL) and 8 AML from myelodysplastic syndrome (MDS/AML). Patients were treated with the JALSG protocol, CAG regimen, or low-dose Ara-C regimen for AML, and DVP/M-CHOP protocol for ALL. The complete remission (CR) rates were 52.7% (29 of 55) in AML, 61.5% (8 of 13) in ALL, and 0% in MDS/AML. The median CR durations were 226, 85, 0 days, and the median survivals were 204, 177, 99 days, respectively. CR rates were 65.3% for the JALSG protocol, 62.5% for the CAG regimen and 25.0% for low-dose Ara-C regimen. According to age, CR was obtained 62.5% in patients aged 60-69 years and 33.3% in patients over 70 years old. Our results indicated that patients aged 60-69 years should be treated with intensive chemotherapy.
AB - A retrospective analysis was performed on 76 consecutive elderly patients with acute leukemia aged 60 years or more (48 men, 28 women). Forty patients were 60-69 years old, 28 were 70-79 years old and 8 were > or = 80 years old. There were 55 patients with acute myelogenous leukemia (AML), 13 acute lymphoblastic leukemia (ALL) and 8 AML from myelodysplastic syndrome (MDS/AML). Patients were treated with the JALSG protocol, CAG regimen, or low-dose Ara-C regimen for AML, and DVP/M-CHOP protocol for ALL. The complete remission (CR) rates were 52.7% (29 of 55) in AML, 61.5% (8 of 13) in ALL, and 0% in MDS/AML. The median CR durations were 226, 85, 0 days, and the median survivals were 204, 177, 99 days, respectively. CR rates were 65.3% for the JALSG protocol, 62.5% for the CAG regimen and 25.0% for low-dose Ara-C regimen. According to age, CR was obtained 62.5% in patients aged 60-69 years and 33.3% in patients over 70 years old. Our results indicated that patients aged 60-69 years should be treated with intensive chemotherapy.
UR - http://www.scopus.com/inward/record.url?scp=0032017875&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0032017875&partnerID=8YFLogxK
M3 - Article
C2 - 9577640
AN - SCOPUS:0032017875
SN - 0485-1439
VL - 39
SP - 176
EP - 184
JO - [Rinshō ketsueki] The Japanese journal of clinical hematology
JF - [Rinshō ketsueki] The Japanese journal of clinical hematology
IS - 3
ER -